Plain-English translation of NCT04442516 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This Canadian research study is looking for early warning signs of kidney damage caused by cisplatin, a powerful chemotherapy drug used to treat many cancers. By studying patterns in blood and urine samples from patients receiving this medication, researchers hope to identify which patients are at highest risk—and catch kidney problems before they cause serious harm.
Cisplatin is an excellent cancer fighter, but it damages the kidneys in 20 to 50% of patients. Right now, doctors can only detect kidney damage after it has already caused loss of function, when it's too late to prevent it. This study aims to find earlier warning signs so doctors can protect patients' kidneys before irreversible damage occurs.
You likely qualify if…
You likely don't qualify if…
As a participant, you would provide blood and urine samples before you start cisplatin chemotherapy and again shortly after you begin treatment. The study team will analyze these samples to look for metabolite patterns that might predict kidney damage risk. This is an observational study—your regular cancer treatment continues as planned, and participation simply involves providing samples at key timepoints to help researchers learn how to protect future patients.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Canada